ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0292

Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis

Amir Razmjou1, Jennifer Wang2, Ani Shahbazian2, Srinivasa Reddy3 and Christina Charles-Schoeman2, 1University of California Los Angeles Medical Center, Los Angeles, CA, 2Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 3David Geffen School of Meicine, UCLA, Los Angeles, CA

Meeting: ACR Convergence 2021

Keywords: Lipids, Lung, paraoxonase, rheumatoid arthritis, Small Airways

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Lung disease in patients with rheumatoid arthritis (RA) is common and associates with significantly increased morbidity and mortality. Oxidative stress plays an important role in the inflammatory responses in airway diseases such as asthma and COPD, but has not been fully investigated in RA-associated lung disease (RA-LD). In the current work, we evaluated associations of the biochemical and genetic determinants of the anti-oxidant HDL-associated protein, paraoxonase 1 (PON-1), and measures of systemic oxidative stress with the presence of RA-LD in a longitudinal RA cohort.

Methods: This study was conducted as a retrospective chart review of a longitudinal single-center cohort of 250 RA patients. All RA patients with an available computed tomographic (CT) scan of the chest were included in the analysis. Scans were reviewed by the interpreting radiologist for the presence of interstitial lung disease (ILD), bronchiectasis, pulmonary fibrosis, centrilobular emphysema, and small airways disease (SAD). SAD was defined by the presence of peribronchial thickening, air trapping, or centrilobular nodularity. PON-1 activity was measured by its lactonase, arylesterase, and paraoxonase activities, the PON-1 Q192R polymorphism, and total plasma oxylipins were measured as described previously (Sci Rep2020 Oct 8;10(1):16848, A&R 2013Nov:65(11):2765-72).

Results: Out of 250 RA patients, 108 (43.2%) had CT scans of the chest available for review. The distribution of lung disease involvement in the cohort (figure 1) included 48 patients (44.4%) with SAD and demonstrated peribronchial thickening in 43 (39.8%), air trapping in 24 (22.2%), and centrilobular nodules in 10 (9.3%). Patients with SAD demonstrated significantly lower PON-1 activity as measured by both arylesterase and lactonase activities and higher levels of several oxylipins compared to patients without SAD (Table 2). Lower PON-1 activities correlated with higher levels of 12-HETE, 15-HETE, and 20-OH LTB4 (r = -0.2- -0.3, p < 0.05). In multivariate logistic regression analyses controlling for known SAD risk factors (RA disease duration, age, sex, smoking, and obesity), lower lactonase and arylesterase activities of PON-1, and higher levels of 12-HETE and 15-HETE remained independently associated with the presence of SAD in RA patients. Such associations were not noted with other types of RA-LD (data not shown).

Conclusion: RA patients with radiographic evidence of SAD demonstrate significantly lower arylesterase and lactonase activities of PON-1 and higher levels of systemic oxidative stress measured by circulating oxylipins, including higher 12-HETE and 15-HETE, which correlated with reduced PON-1 activity. Future studies are warranted to evaluate the relationship of PON-1 and pro-inflammatory oxylipins to the pathogenesis of RA lung disease.


Disclosures: A. Razmjou, None; J. Wang, None; A. Shahbazian, None; S. Reddy, Gut Leben, 2; C. Charles-Schoeman, AbbVie, 2, 5, Bristol-Myers Squibb, 5, Pfizer Inc, 2, 5, Gilead Sciences, 2, Sanofi-Regeneron, 2.

To cite this abstract in AMA style:

Razmjou A, Wang J, Shahbazian A, Reddy S, Charles-Schoeman C. Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/suppressed-paraoxonase-1-activity-and-elevated-oxylipins-associate-with-the-presence-of-small-airways-disease-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppressed-paraoxonase-1-activity-and-elevated-oxylipins-associate-with-the-presence-of-small-airways-disease-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology